Everyone looks up when the lights flicker in a hospital ward. Nurses pause. Families hold their breath. The room discovers how much it trusts a system it cannot fully control. Something like that is happening now in global healthcare.

The contraction of foreign aid has shaken clinics, government ministries, and communities across Africa. But it has also illuminated a deeper truth: vulnerability is not only a matter of scarce resources. It is also a matter of where decision rights are located. Julius Nyerere, one of the founding fathers of modern Africa said, "For any people that depend on others to care for them are in danger of losing their freedom.”

It is a hard lesson

No honest and informed observer can deny what American support has meant over the years. It has helped finance treatment, widen access to vaccines, support disease control, and sustain health systems under pressure. It has often been shaped by people in the United States – scientists, diplomats, advocates, taxpayers – who genuinely believed that their country had a responsibility to stand with others in moments of crisis. Many lives were saved because that support existed.

But gratitude should not prevent reappraisal. The present moment has revealed that a system built too heavily on the budget choices of a distant government, however generous, remains a fragile system. What has been shaken is not only the flow of money. It is the assumption that lasting security can be built on external discretion.

For Rwanda, and for Africa more broadly, that realization should not breed bitterness. It should improve ambition.

Benevolence has limits

The older grammar of aid carried within it an imbalance. One side funded, the other adapted. One side approved, the other implemented. That arrangement too often left ownership elsewhere and reduced sovereignty to administration. Ashraf Ghani was a scholar and a World Banker before he became president of a beleaguered Afghanistan. He said, "Foreign aid severs the sovereign relationship between leadership and the people.”

But health security, like national development, cannot rest forever on benevolence. It must be rooted in capability, stewardship, and the right to decide. The institutions closest to the burden of disease must have the authority to shape the response, hold the assets, and carry the vision beyond the life of a grant cycle.

This is why the present disruption, painful though it is, may prove clarifying. It has exposed the weakness of a model that confused support with durability. And it has created an opening to build something stronger.

What partnership should mean

We should not turn away from the United States. America still possesses extraordinary gifts: great universities, scientific imagination, pharmaceutical talent, manufacturing know-how, logistical sophistication, regulatory experience, and pools of risk capital willing to back bold ideas. These remain among the great treasures of the modern world. And they are the true gifts of the global North when they are offered with humility and received with dignity.

The task, then, is not withdrawal from America, but a wiser engagement. Africa does not need a relationship defined mainly by annual appropriations from the legislature in Washington, the majority of whom have not been to Africa or even own a passport. It needs relationships that draw on the best of American capacity while placing African ownership at the center of the enterprise.

That is the difference between assistance and partnership. Assistance helps one endure the present. Partnership can help one become what Paul Kagame has said, "Not prisoners of our history,” but "authors of our future.”

Why AKAGERA Medicines matters

This is where AKAGERA Medicines becomes more than a company. It becomes a new proposition. It suggests that African institutions can do more than receive solutions; they can build them. And they are stronger when they do it together. The Ethiopians say, "When spiders unite, they can tie up a lion.” They can identify the diseases that remain neglected, cross borders to assemble the science and talents required to confront them and create enterprises whose first loyalty is to the people who bear the burden, own the company, and make the strategy.

Founded as a Rwandan-owned biopharmaceutical platform, AKAGERA Medicines was built to translate this philosophy into practice—advancing the discovery, development, and manufacturing of vaccines and biologics that address both regional and global health priorities. Its portfolio focuses on high-impact infectious diseases, including RSV, avian influenza, and other under-served threats, while also building the scientific, regulatory, and manufacturing capabilities required to sustain innovation on the continent. In doing so, it aims not only to deliver products, but to anchor a durable ecosystem of African-led research, clinical development, and production.

That matters because the market does not naturally rush on time toward every human need. Diseases that weigh heavily on African societies rarely, if ever, command the urgency they deserve from global pharmaceutical firms.

Nor can bilateral aid be expected to sustain the long horizon of product development. There are ailments the market overlooks and public finance treats episodically. In that gap, African-owned companies with courage and discipline have a special role to play.

AKAGERA Medicines fills such a role. In this model, African actors hold the mission, the priorities, and the decision rights. American institutions bring what they do best—science, systems, infrastructure, manufacturing knowledge, and risk capital. The relationship becomes not donor and recipient, but co-builders of something neither could achieve alone.

Rwanda is especially well placed to think in these terms. The country has spent decades showing that serious institutions, disciplined leadership, and a refusal to be imprisoned by inherited limitations can produce uncommon results.

That national habit of building with intention is precisely what this moment demands. Unlike previous aid models, which depended on external generosity and short grant cycles, RSSB’s strategy turns Rwandans’ own savings into patient, domestically-governed capital, placing ownership firmly in Rwandan hands. Their CEO, Regis Rugemanshuro, noted, "Rwanda has set ambitious targets to become a high-income nation by 2050, and we are fully committed to this vision by aligning our capital to the key pillars in priority sectors.”

The question before us

Rwanda is not simply asking how to replace one stream of aid with another. It is asking how to convert uncertainty into capacity. How to ensure that the next generation of health security is not borrowed but built. How to move from being a site where programs land to being a place where strategies are imagined, owned, and carried through.

That is not a rejection of the world. It is a mature invitation to it. Come with knowledge. Come with technology. Come with capital. Make a partnership. But come prepared to help strengthen African institutions whose assets, operations, and strategy are shaped by African owners.

After the flicker

The withdrawal of traditional programs has hit hard, and no one should underestimate that pain. There are real human consequences when support recedes. But history sometimes advances by exposing the weakness of arrangements once mistaken for permanence.

If this moment leads to stronger African-owned institutions, more serious public-private alliances, and a deeper form of collaboration with the United States and other partners, then something important will be gained.

The destination is not separation from America. It is freedom from the kind of dependence that leaves a nation’s health horizon vulnerable to decisions made elsewhere.

When the lights flicker, a room learns what it has failed to secure. It also learns what must now be built. Perhaps this is such a moment for African healthcare: a moment to create a stronger "grid,” one in which African ownership provides "the power,” American capacity helps extend "the line,” and the future is no longer something delivered from abroad, but something made deliberately, strategically, and at last—in the Heart of Africa.

The authors are executives and scientists of Rwandan-owned AKAGERA Medicines.